MEK1/2-ERK1/2 signaling inhibition in ovarian cancer cells is reported to sensitize them to chemotherapy [57], so MEK1/2 pathway hyperactivation could be a mechanism allowing HGSOC cells to overcome cytotoxic effects of cisplatin. This evidence concerns the gene MAPK3 and ovarian cancer.